ClinicalTrials.gg

TargetBeta

HRH1

histamine receptor H1 · Histamine receptors

4 programs in company-led studies act on HRH1, from 4 companies: 0 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
DiphenhydramineruleJohnson & Johnsonphase 4161 running–ChEMBL
desloratadineruleOrganonphase 4400 running–ChEMBL
fexofenadineruleSanofiphase 4380 running–ChEMBL
bilastineruleFaes Farmaphase 4190 running–ChEMBL

Conditions their studies are in

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.